## Paula A Desplats

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4673597/publications.pdf

Version: 2024-02-01

55 papers 7,150 citations

94269 37 h-index 52 g-index

57 all docs

57 docs citations

57 times ranked

9616 citing authors

#	Article	IF	CITATIONS
1	Differential blood DNA methylation across Lewy body dementias. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12156.	1.2	7
2	Non-invasive biomarkers of fetal brain development reflecting prenatal stress: An integrative multi-scale multi-species perspective on data collection and analysis. Neuroscience and Biobehavioral Reviews, 2020, 117, 165-183.	2.9	31
3	Microglial memory of early life stress and inflammation: Susceptibility to neurodegeneration in adulthood. Neuroscience and Biobehavioral Reviews, 2020, 117, 232-242.	2.9	34
4	Perfect timing: circadian rhythms, sleep, and immunity â€" an NIH workshop summary. JCI Insight, 2020, 5,	2.3	136
5	DNA methylation changes associated with Parkinson's disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood. Epigenetics, 2019, 14, 365-382.	1.3	58
6	Alterations in Striatal microRNA-mRNA Networks Contribute to Neuroinflammation in Multiple System Atrophy. Molecular Neurobiology, 2019, 56, 7003-7021.	1.9	22
7	Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington's Disease Patients. Frontiers in Molecular Neuroscience, 2019, 12, 335.	1.4	41
8	Identification of Insulin Receptor Splice Variant B in Neurons by in situ Detection in Human Brain Samples. Scientific Reports, 2018, 8, 4070.	1.6	14
9	P2â€195: AMYLOID BETA INDUCES ABERRANT DNA METHYLATION TRANSITIONS THAT ACTIVATE MICROGLIA. Alzheimer's and Dementia, 2018, 14, P743.	0.4	O
10	Alterations in brain <scp>TREM</scp> 2 and Amyloidâ€Î² levels are associated with neurocognitive impairment in <scp>HIV</scp> â€infected persons on antiretroviral therapy. Journal of Neurochemistry, 2018, 147, 784-802.	2.1	28
11	Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathologica Communications, 2017, 5, 2.	2.4	41
12	Circadian alterations during early stages of Alzheimer's disease are associated with aberrant cycles of DNA methylation in BMAL1. Alzheimer's and Dementia, 2017, 13, 689-700.	0.4	83
13	MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy. Frontiers in Molecular Neuroscience, 2017, 10, 329.	1.4	43
14	Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity. Journal of Neuroinflammation, 2016, 13, 120.	3.1	34
15	P3â€107: Alterations in DNA Methylation Contribute to Neuroinflammation in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P860.	0.4	O
16	A <i>de novo</i> compound targeting α-synuclein improves deficits in models of Parkinson's disease. Brain, 2016, 139, 3217-3236.	3.7	122
17	Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. Journal of Neuroscience, 2016, 36, 7971-7984.	1.7	44
18	α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Human Molecular Genetics, 2016, 25, 1100-1115.	1.4	45

#	Article	IF	CITATIONS
19	Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease. Journal of Neuroinflammation, 2015, 12, 236.	3.1	29
20	Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson's Disease. Journal of Experimental Neuroscience, 2015, 9s2, JEN.S25521.	2.3	5
21	Perinatal Programming of Neurodevelopment: Epigenetic Mechanisms and the Prenatal Shaping of the Brain. Advances in Neurobiology, 2015, 10, 335-361.	1.3	27
22	Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease. Stem Cell Research, 2015, 15, 54-67.	0.3	37
23	ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo. Molecular Therapy, 2014, 22, 1753-1767.	3.7	80
24	P4-204: NEURO-PEPTIDE TREATMENT WITH CEREBROLYSIN IMPROVES THE SURVIVAL OF NEURAL STEM CELL GRAFTS IN THE APP TRANSGENIC MODEL OF ALZHEIMER'S DISEASE. , 2014, 10, P863-P863.		1
25	Structural Diversity of Alzheimer's Disease Amyloid- $\hat{l}^2$ Dimers and Their Role in Oligomerization and Fibril Formation. Journal of Alzheimer's Disease, 2014, 39, 583-600.	1.2	26
26	Hippocampal neuronal cells that accumulate $\hat{l}$ ±-synuclein fragments are more vulnerable to $\hat{Al}^2$ oligomer toxicity via mGluR5 $\hat{a}$ €" implications for dementia with Lewy bodies. Molecular Neurodegeneration, 2014, 9, 18.	4.4	53
27	A Neuroprotective Brain-penetrating Endopeptidase Fusion Protein Ameliorates Alzheimer Disease Pathology and Restores Neurogenesis. Journal of Biological Chemistry, 2014, 289, 17917-17931.	1.6	36
28	Epigenetic Alterations in the Brain Associated with HIV-1 Infection and Methamphetamine Dependence. PLoS ONE, 2014, 9, e102555.	1.1	40
29	Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology, 2013, 80, 1415-1423.	1.5	160
30	Distinctive patterns of DNA methylation associated with Parkinson disease. Epigenetics, 2013, 8, 1030-1038.	1.3	275
31	TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson's Disease. PLoS ONE, 2013, 8, e62277.	1.1	133
32	Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Human Molecular Genetics, 2012, 21, 3097-3111.	1.4	55
33	Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission. Journal of Neuroscience, 2012, 32, 13454-13469.	1.7	290
34	Increased Calcium Influx and Decreased Buffering Capacity of Intracellular Stores Underlie Neuropathology Induced by Over-Expression of α-Synuclein. Biophysical Journal, 2012, 102, 424a-425a.	0.2	0
35	α-Synuclein Induces Alterations in Adult Neurogenesis in Parkinson Disease Models via p53-mediated Repression of Notch1. Journal of Biological Chemistry, 2012, 287, 31691-31702.	1.6	64
36	Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease. Molecular Neurodegeneration, 2012, 7, 49.	4.4	63

3

#	Article	IF	CITATIONS
37	In Vivo Alterations in Calcium Buffering Capacity in Transgenic Mouse Model of Synucleinopathy. Journal of Neuroscience, 2012, 32, 9992-9998.	1.7	36
38	Role of αâ€synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS Journal, 2012, 279, 1000-1013.	2.2	146
39	Cell-to-Cell Transmission of α-Synuclein Aggregates. Methods in Molecular Biology, 2012, 849, 347-359.	0.4	45
40	α-Synuclein Sequesters Dnmt1 from the Nucleus. Journal of Biological Chemistry, 2011, 286, 9031-9037.	1.6	258
41	Increased CDK5 Expression in HIV Encephalitis Contributes to Neurodegeneration via Tau Phosphorylation and Is Reversed with Roscovitine. American Journal of Pathology, 2011, 178, 1646-1661.	1.9	56
42	In vivo demonstration that $\hat{l}_{\pm}$ -synuclein oligomers are toxic. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4194-4199.	3.3	1,252
43	Cell-to-cell transmission of non-prion protein aggregates. Nature Reviews Neurology, 2010, 6, 702-706.	4.9	269
44	Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntington's disease. Journal of Neurochemistry, 2010, 115, 748-758.	2.1	36
45	Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-Synucleinopathy. PLoS ONE, 2010, 5, e9313.	1.1	327
46	Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy $\hat{a}\in$ Implications for Excitotoxicity. PLoS ONE, 2010, 5, e14020.	1.1	66
47	Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13010-13015.	3.3	1,308
48	Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Experimental Neurology, 2009, 219, 543-552.	2.0	133
49	Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease. Neurobiology of Disease, 2008, 31, 298-308.	2.1	63
50	α-Synuclein Alters Notch-1 Expression and Neurogenesis in Mouse Embryonic Stem Cells and in the Hippocampus of Transgenic Mice. Journal of Neuroscience, 2008, 28, 4250-4260.	1.7	127
51	The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15564-15569.	3.3	271
52	Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases. PLoS ONE, 2008, 3, e3135.	1.1	233
53	Glycolipid and ganglioside metabolism imbalances in Huntington's disease. Neurobiology of Disease, 2007, 27, 265-277.	2.1	120
54	Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. Journal of Neurochemistry, 2006, 96, 743-757.	2.1	125

#	Article	IF	CITATIONS
55	Chemotaxis of Silicibacter sp. Strain TM1040 toward Dinoflagellate Products. Applied and Environmental Microbiology, 2004, 70, 4692-4701.	1.4	119